Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Jerome Stevens Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Jerome Announces Acquisition of Thyquidity (Levothyroxine Sodium Oral Solution)
Details : Jerome acquires Thyquidity (levothyroxine sodium) from Azurity. It is indicated for the treatment of Hypothyroidism.
Product Name : Thyquidity
Product Type : Hormone
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Jerome Stevens Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZURITY Wins FDA Approval for DANZITEN™ Tablets with No Mealtime Restrictions
Details : Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.
Product Name : Danziten
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolate Mofetil
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azurity Announces FDA Approval Of Myhibbin™ Oral Suspension
Details : Myhibbin (mycophenolate mofetil) is an immunosuppressive agent acting as an inosine monophosphate dehydrogenase (IMPDH) inhibitor, indicated for preventing organ rejection in transplant patients.
Product Name : Myhibbin
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : Mycophenolate Mofetil
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azurity Pharmaceuticals’ NYMALIZE® Oral Solution Approved by FDA
Details : Nymalize is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, approved for treating aneurysmal subarachnoid hemorrhage patients.
Product Name : Nymalize
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2024
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Azurity Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Azurity Pharmaceuticals Acquires Slayback Pharma
Details : Through the acquisition, Azurity gains access to Slayback's pipeline including, Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.
Product Name : Precedex-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Azurity Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : EdiGene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : EdiGene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.
Product Name : Brimonidine Tartrate-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 29, 2022
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Lumify® is an over-the-counter (OTC) eyedrop having Brimonidine Tartrate that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
Product Name : Brimonidine Tartrate-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 29, 2022
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Zonisamide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Zonisade™ (Zonisamide Oral Suspension)
Details : ZONISADE is first and only zonisamide formulation for oral liquid administration to be approved by FDA, as an adjunctive therapy for the treatment of partial seizures in adults and pediatric patients aged 16 years and older with epilepsy.
Product Name : Zonisade
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : Zonisamide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Merzee® Capsules in the United States
Details : U.S.FDA has approved Abbreviated New Drug Application for Merzee (Slayback Pharma), an AB-rated generic equivalent of Taytulla® (Allergan), an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.
Product Name : Merzee
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable